 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases...

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Duchenne is a genetic disorder, primarily affecting boys and is known to be fatal. This disease is claimed to affect roughly one in every 3,500 to 5,000 live
The post Solid Biosciences' SGT-003...

Solid Biosciences' SGT-003 receives rare pediatric disease designation

This indicator may be signaling that SLDB's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Solid Biosciences (SLDB, $12.44) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

This is a Bearish indicator signaling SLDB's price could decline from here. Traders may explore shorting the stock or put options...

Solid Biosciences (SLDB, $12.44) Moving Average Convergence Divergence (MACD) Histogram turned negative on April 1, 2024

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Solid Biosciences receives Rae Pediatric Disease designation for SGT-003

SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 CHARLESTOWN, Mass...

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Solid Biosciences (NASDAQ:SLDB - Get Free Report)s stock had its "outperform" rating reissued by stock analysts at William Blair in a research note issued on Thursday, MarketBeat reports. A...

William Blair Reaffirms Outperform Rating for Solid Biosciences (NASDAQ:SLDB)

Solid Biosciences initiated with bullish view at William Blair, here's why

William Blair starts Solid Biosciences at outperform...

William Blair starts Solid Biosciences at outperform

CHARLESTOWN, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases...

Solid Biosciences to Participate at Cantor's Virtual Muscular Dystrophy Symposium

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Volume (M)	54,137.00
52-Wk High	$15.05
52-Wk Low	$1.81

SLDB Solid Biosciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals